Research programme: inflammatory bowel disease therapeutics - Amgen/Broad Institute/Massachusetts General Hospital
Latest Information Update: 28 Feb 2018
At a glance
- Originator Amgen; Broad Institute; Massachusetts General Hospital
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Inflammatory-bowel-disease in USA
- 15 Jan 2014 Early research in Inflammatory bowel disease in USA (unspecified route)